Haleon completes acquisition of remaining 12% stake in China JV

Published 27/06/2025, 10:06
Haleon completes acquisition of remaining 12% stake in China JV

LONDON - Haleon plc (LSE/NYSE:HLN) has completed the acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical (TADAWUL:2070) Co. Ltd (TSKF), its over-the-counter joint venture in China, the company announced Friday.

The transaction, which was previously announced on April 15, 2025, was finalized for a total consideration of RMB 1,623 million (approximately £0.2 billion). Following the completion, TSKF has become a wholly owned subsidiary of Haleon.

TSKF accounted for approximately 40% of Haleon’s China revenues in 2024 and manufactures and distributes brands including Fenbid, Voltaren and Bactroban. The joint venture has operated with what the company describes as a long heritage of operational excellence in the Chinese market.

China represents a key market for Haleon, with the company citing favorable structural drivers underpinning its business there. According to the press release statement, the acquisition aims to provide Haleon with increased strategic and operational flexibility in one of the fastest growing OTC markets globally.

The company stated that the acquisition aligns with its capital allocation priorities to drive returns for shareholders while maintaining a strong investment grade balance sheet.

Haleon is a global consumer health company whose portfolio spans six major categories including oral health, vitamins and supplements, pain relief, respiratory health, digestive health, and therapeutic skin health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.